Jean-Jacques Kiladjian

40PUBLICATIONS
178CO-AUTHORS
PharmacogenomicsCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsGene expression (incl. microarray and other genome-wide approaches)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (40)

|Oct 13, 2026
VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy.

|Oct 07, 2026
Navitoclax monotherapy or in combination with ruxolitinib in patients with JAK2 inhibitor-treated myelofibrosis: results from the phase 2 REFINE and phase 3 TRANSFORM-2 studies.

|Jun 30, 2026
TRANSFORM-1 phase 3 study: efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis.

|Apr 17, 2026
Scalable genotyping in fixed transcriptomes resolves clonal heterogeneity via single-cell sequencing.

|Mar 05, 2026
Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis.

Barbara Mora, Francesca Palandri, Paola Guglielmelli

|Mar 04, 2026
Myeloid/lymphoid neoplasms with FGFR1 rearrangement and pemigatinib.

Alessandro M Vannucchi, Jay L Patel, Jean-Jacques Kiladjian

Pageof 7

Frequent Collaborators

10 joint publications

Bruno Cassinat

9 joint publications

Alessandro Vannucchi

8 joint publications

John Mascarenhas

7 joint publications

Srdan Verstovsek